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Abstract
Withaferin A (WFA), a steroidal lactone, negatively regulates breast cancer growth however, its mechanisms of action 
remain largely elusive. We found that WFA blocks autophagy flux and lysosomal proteolytic activity in breast cancer 
cells. WFA increases accumulation of autophagosomes, LC3B-II conversion, expression of autophagy-related proteins and 
autophagosome/lysosome fusion. Autolysosomes display the characteristics of acidic compartments in WFA-treated cells; 
however, the protein degradation activity of lysosomes is inhibited. Blockade of autophagic flux reduces the recycling of 
cellular fuels leading to insufficient substrates for tricarboxylic acid (TCA) cycle and impaired oxidative phosphorylation. 
WFA decreases expression and phosphorylation of lactate dehydrogenase, the key enzyme that catalyzes pyruvate-to-
lactate conversion, reduces adenosine triphosphate levels and increases AMP-activated protein kinase (AMPK) activation. 
AMPK inhibition abrogates while AMPK activation potentiates WFA’s effect. WFA and 2-deoxy-d-glucose combination 
elicits synergistic inhibition of breast cancer cells. Genetic knockout of BECN1 and ATG7 fails to rescue cells from WFA 
treatment; in contrast, addition of methyl pyruvate to supplement TCA cycle protects WFA-treated cells. Together, these 
results implicate that WFA is a potent lysosomal inhibitor; energetic impairment is required for WFA-induced apoptosis and 
growth inhibition and combining WFA and 2-DG is a promising therapeutic strategy for breast cancer.
Introduction
Despite various improved diagnostic techniques and the 
development of targeted therapeutic approaches, breast cancer 
is still the second leading cause of cancer-related mortality in 
women. Ongoing quests to develop more effective, nontoxic 
and nonendocrine strategies to target breast cancer have now 
focused on bioactive compounds from natural products and 
a review of epidemiologic, in vitro and in vivo studies provides 
robust support for the suitability and efficacy of several bioactive 
compounds for future clinical development. The root extract of 
Withania somnifera, exhibiting broad-spectrum pharmacological 
efficacy, has been successfully used in traditional alternative 
medicine (1–3) and its therapeutic benefits are attributed to 
14 bioactive compounds called withanolides (4,5). Among 
these withanolides, withaferin A  (WFA) is the most abundant 
and therapeutically effective withanolides with anti-cancer 
activities (6–8). WFA protects against acetaminophen-induced 
hepatic toxicity (9) and bromobenzene (an environmental 
toxin)-induced liver and kidney damage (10). Some clinical trials 
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have investigated the efficacy of W.somnifera extracts (Drug: 
Sensoril) for bipolar disorder, schizophrenia and generalized 
anxiety disorder (ClinicalTrials.gov Identifier: NCT00761761, 
NCT01311180, NCT01793935) and Schlicht and group reported 
that W.somnifera extracts provided significant benefits in 
patients with schizophrenia (11). Previous studies from our 
lab (12) and others (13) have shown that WFA administration 
decreases breast cancer growth in vitro and in vivo. On one 
hand WFA has been shown to induce apoptosis (14), effectively 
inhibit oncogenic transcription factor Stat3 (15), and activate 
death receptor 5 (DR5) (12) leading to effective inhibition of 
breast tumors but on the other hand it has also been reported 
to activate Notch signaling which is involved in growth and 
progression of breast cancer (16). Thus, developing a complete 
functional understanding of therapeutic impact of WFA on 
breast cancer is required to establish surrogate biomarkers and 
further clinical development of WFA.
Cells, in normal physiological conditions, undergo 
macroautophagy (referred to as autophagy hereafter), a 
self-degradation process where cytosolic components and 
organelles are recycled using a vacuolar, lysosomal degradation 
pathway to maintain cellular homeostasis and provide energy 
in stressed state (17,18). Basal autophagy helps prevent accu-
mulation of damaged proteins and organelles, lower ER stress 
and reduce the production of reactive oxygen species. Recent 
studies, using multiple model systems, have shown that can-
cer cells utilize autophagic process to respond to various 
environmental stimuli and evade cancer therapy. Autophagy 
is a complex process involving concerted action of various 
autophagy-related (ATG) proteins forming a double-membrane 
bound vacuole known as autophagosome. Following maturation 
and fusion processes (fusing with endocytic compartments 
like early and late endosomes), autophagosomes fuse with 
the lysosomal compartments to form autolysosomes where 
cargo is degraded to produce energy. Although autophagy is a 
multistep process, increased number of autophagosome in cyto-
sol is generally used to evaluate autophagic induction but accu-
mulation of autophagosomes can result from either increased 
formation or decreased turnover of autophagosome. Therefore, 
it is imperative to examine the entire process of autophagy, 
known as autophagic flux, to comprehend the involvement 
and functional impact of autophagy pertaining to anti-cancer 
regimens.
In this study, we examined the involvement of autophagy 
in WFA-mediated growth inhibition and apoptosis induction in 
breast cancer cells. We report that WFA inhibits the autophagic 
flux in breast cancer cells by abrogating the protein degrad-
ation activity of lysosomes without altering the integrity of the 
other steps of autophagic process such as autophagosome accu-
mulation, LC3B-II conversion and fusion of autophagosome/
lysosomes. Blocking autophagic flux can reduce the recycling of 
cellular fuels resulting in insufficient substrates for tricarboxylic 
acid (TCA) cycle and impaired oxidative phosphorylation. Indeed, 
WFA treatment decreases adenosine triphosphate (ATP) levels, 
activates AMP-activated protein kinase (AMPK) and decreases 
the expression/phosphorylation of lactate dehydrogenase 
(LDHA) impacting pyruvate-to-lactate conversion. Blunting 
autophagosome formation, blocking autophagosome–lysosome 
fusion or genetic knockout of BECN1 and ATG7 fail to rescue 
cells from WFA treatment but addition of methyl pyruvate to 
supplement TCA cycle protects WFA-treated cells. Also, AMPK 
inhibition interferes with WFA efficacy while AMPK activation 
potentiates it. In fact, WFA and 2-DG show synergistic inhibition 
of breast cancer cells indicating that a combined regimen of 
WFA and 2-DG can be a promising therapeutic strategy. Together, 
these results implicate that WFA is a potent lysosomal inhibitor 
and impedes growth and induces apoptosis in breast cancer 
cells via energetic impairment.
Materials and methods
Ethics statement
Xenograft tumor samples/sections are from our previously published 
study (12). All animal studies were in accordance with the guidelines of 
Johns Hopkins University IACUC.
Cell culture and reagents
Breast cancer cell lines MCF7, MDA-MB-231, MDA-MB-468, T47D were 
obtained from the American Type Culture Collection (HTB-22, HTB-26, 
HTB-132, HTB-133). SUM149 and SUM159 were procured from Asterand 
Bioscience (Detroit, MI). These cell lines were authenticated in 2014 
and each cell line was of human origin and no inter species contamin-
ation was found. Cell lines were maintained according to supplier’s 
recommendation. Frozen stocks of authenticated cell lines were used. 
WFA was purchased from Calbiochem. Our preliminary dose-dependent 
and time-dependent studies showed that 5 µM WFA is an effective dose in 
breast cancer cells therefore we treated breast cancer cells with 5 µM WFA. 
Antibodies for MAP1LC3B/LC3B (3868), ATG5 (12994), ATG7 (8558), BECN1 
(3495), STK11/LKB1 (3050), cleaved PARP1 (5625), PARP1 (9532), PRKAA1 
(2532), phospho-PRKAA1 (Thr172) (2535), LDHA (3582) and phospho-LDHA 
(Tyr10) (8176) and SQSTM1/p62 (5114) were purchased from Cell Signaling 
Technology. ACTB/β-actin (A5441) antibody, 3-methyladenine (3-MA; 
M9281), chloroquine (CQ; C6628), rapamycin (R0395), 2-deoxy-d-glucose 
(2-DG; D6134), methyl pyruvate (371173) were purchased from Sigma–
Aldrich. LysoTracker Red DND-99 (L7528) was purchased from Invitrogen. 
Bafilomycin (11038) was purchased from Cayman Chemical. DQ™ Green 
BSA assay (D12050), Earle’s balanced salt solution (EBSS; 14155-063), Alexa 
Fluor 488 (A-11008) and Alexa Fluor 555 (A-21428) were purchased from 
Thermo Fisher Scientific.
Clonogenicity and cell viability assay
Anchorage-dependent clonogenicity assay (19) was conducted in 
the presence of WFA. Colonies containing >50 normal appearing 
cells were counted and pictures were taken using a digital camera. 
Viability was examined using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay (Thermo Fisher Scientific, M6494) 
following the manufacturer’s instructions.
Abbreviations 
2-DG 2-deoxy-d-glucose
3-MA 3-methyladenine
ACTB actin
AMPK AMP-activated protein kinase
ATG5 autophagy related 5
ATG7 autophagy related 7
ATP adenosine triphosphate
BECN1 beclin 1
CQ chloroquine
GFP green fluorescent protein
MAP1LC3B/LC3B microtubule-associated protein 1 
light chain 3 beta
LDHA lactate dehydrogenase A
MP methyl pyruvate
mRFP monomeric red fluorescent protein
PARP1 poly(ADP-ribose) polymerase1
PRKAA1 protein kinase
AMP activated, alpha 1 catalytic subunit
RFP red fluorescent protein
SQSTM1/p62 sequestosome 1
WFA withaferin A
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Transmission electron microscopy, 
immunofluorescence and confocal imaging 
Breast cancer cells were treated with WFA or vehicle control for 3 or 6 h, 
specimens were embedded in EPON, sectioned, stained and examined 
with an H7600 transmission electron microscope (Hitachi, Tokyo, Japan). 
Cells were fixed and immunofluorescently stained (20) followed by 
imaging using a Zeiss LSM510 Meta (Zeiss, Dublin, CA) laser scanning con-
focal system configured to a Zeiss Axioplan 2 upright microscope (Zeiss).
Immunoblotting
Cells were scraped in modified RIPA buffer to prepare whole cell lysates and 
subjected to immunoblotting (12,21). For RNA isolation and RT-PCR (22,23), 
total cellular RNA was extracted using the TRIzol Reagent (ThermoFisher 
Scientific, 15596026) and RT-PCR was performed using specific sense and 
antisense PCR primers.
Breast tumorigenesis assay
MDA-MB-231 cells xenografts from our previously published study (12) 
were used to determine the effect of WFA on autophagy. All animal studies 
were in accordance with the guidelines of Johns Hopkins University IACUC.
Apoptosis, acridine orange staining
Cells were cultured on chamber slides, treated with WFA followed by 
Hoechst 33342 staining (Thermo Fisher Scientific, H1399) according to the 
manufacturer’s protocol. Breast cancer cells were cultured on six-well 
plates and treated with vehicle or 2.5 µM or 5 µM WFA for 24 h followed 
by incubation with acridine orange (Sigma–Aldrich, A9231) and were 
examined with confocal microscope (24).
ATG7 and BECN1 knockout with CRISPR/Cas9
Digested and purified LentiCRISPRv2 plasmid [lentiCRISPRv2 was a gift 
from Feng Zhang (Addgene, 52961)] was incubated with phosphorylated, 
annealed oligos for ATG7 and BECN1 in a ligation reaction, transformed into 
Stbl3 bacteria (ThermoFisher Scientific, C7373-03). lentiCRISPR with inserted 
sequences were cotransfected into HEK293T cells with packinging plasmids. 
MCF7 cells were transfected twice and selected for a week. MCF7 cells were 
examined for the ATG7 and BECN1 knockout using immunoblot analyses.
ATP assay
Cells were treated with vehicle or WFA for 1, 3, 6, 12 or 24 h, lysed in cell 
lysis solution (Perkin Elmer, 6016739), substrate solution was added and 
ATP levels were detected by measuring luminescence. ATP levels were 
measured using the ATPlite luminescence assay system (Perkin Elmer, 
6016739) according to the manufacturer’s instructions.
Survival analysis
We assessed the correlation between AMPK and LDHA expression and survival 
using an independent multicentre gene expression database established as 
described previously (PMID: 23836010). All samples were measured using 
Affymetrix HGU133A or HUG133 plus 2 gene chips. We performed Cox 
proportional hazards regression analysis to correlate expression and relapse-
free survival and Kaplan–Meier plots were drawn for visualization.
Statistical analysis
All experiments were performed multiple times using independent bio-
logical replicates. Statistical analysis was performed using Microsoft Excel 
software. Significant differences were analyzed using the Student’s t-test 
and two-tailed distribution. Results were considered to be statistically 
significant if P <0.05. Results were expressed as mean ± SE between 
triplicate experiments performed thrice.
Results
WFA inhibits breast cancer growth and increases 
intracellular autophagosomes and autophagy markers
WFA exerted a significant decrease in anchorage-dependent 
clonogenicity and cell viability in a concentration dependent 
manner and more effective inhibition was observed with 
5–12.5 μM WFA treatment. Breast cancer is a heterogeneous 
disease and gene expression profiling has revealed five 
molecular subtypes (25) of clinical implications therefore 
WFA-mediated growth inhibition was corroborated in breast 
cancer cells spanning multiple subtypes including luminal 
A  (MCF7, T47D), luminal B (BT474), basal (MDA-MB-468, 
SUM149), claudin-low (MDA-MB-231, SUM159), HER2 (SKBR3) 
(Supplementary Figures S1A and B, S2A–D, S3A–D, S4A–C, 
available at Carcinogenesis Online). WFA-mediated inhibition of 
breast cancer growth was associated with increased apoptotic 
cell death (Supplementary Figure S5, available at Carcinogenesis 
Online). Next, we examined the ability of WFA to induce 
autophagy in breast cancer cells. Using transmission electron 
microscopy (TEM), we observed ultrastructural changes in 
cells treated with 5 μM WFA within 3 and 6 h post-treatment. 
WFA-treated cells acquired significantly higher number (3- 
to 10-fold increase) of autophagic vacuoles in comparison 
to control cells (Figure 1A). Formation of autophagosomes 
is accompanied with a marked redistribution of MAP1LC3B/
LC3B (microtubule-associated protein 1 light chain 3  α) 
from the cytosol to autophagosomes. Confocal microscopy 
detected increased LC3B puncta formation in WFA-treated 
MCF7, MDA-MB-231, MDA-MB-468, SUM149 and SUM159 cells 
while a diffuse, cytoplasmic green fluorescence was observed 
in control cells (Figure 1B). LC3B-I to LC3B-II conversion is an 
important sign of autophagy activity (26) and WFA treatment 
resulted in increased time-dependent accumulation of LC3B-II 
(Figure 1C). These in vitro observations were corroborated 
using MDA-MB-231 xenograft-tumors and immunoblotting 
of tumor lysates from WFA-treated mice showed increased 
expression of LC3B-II in comparison to tumors from vehicle-
treated mice (Figure 1D). Immunohistochemical analysis also 
showed increased expression of LC3B-II in breast tumors 
from WFA-treated mice while tumors from vehicle-treated 
mice exhibited low LC3B-II staining (Figure 1F). In addition 
to augmented LC3B-conversion, mRNA level and protein 
expression of other autophagy-related (ATG) markers, such 
as ATG5, ATG7 and BECN1 were also increased upon WFA 
treatment. Some ATG proteins (such as ATG5) showed a 
sustained increase in expression while others (e.g. Beclin) 
showed a transient increase in expression in response to 
WFA. Of note, all ATG proteins exhibited increased expression 
upon 6-h WFA treatment (Figure 1E and G). Augmented 
LC3B-II puncta and expression levels correlate either with an 
increase in autophagosomes synthesis or with a decrease in 
autophagosomes turnover resulting from delayed trafficking 
to the lysosomes and decreased fusion with lysosomes 
(27). To discriminate between these two scenarios in WFA-
treated cells, we utilized a plasmid encoding membrane-
localized red fluorescent protein (mRFP)-EGFP-LC3B (tandem 
fluorescent-tagged LC3B [tfLC3B]) (28). This probe results 
in both green and red fluorescence and is used to identify 
autophagosomes (green flurescent protein [GFP]-positive 
and red flurescent protein [RFP]-positive; merged as yellow) 
and autolysosomes (GFP-negative and RFP-positive; merged 
as red) because enhanced green fluorescent protein (EGFP) 
fluorescence is quenched in acidic compartments whereas 
mRFP is more stable in low pH environment. Breast cancer 
cells were transfected with tfLC3B, treated with WFA and 
distribution of mRFP-EGFP-LC3B fusion protein was analyzed. 
MDA-MB-231 and MCF7 cells exhibited an increase in both 
red and yellow punctate fluorescence upon WFA treatment 
(Figure 1H) indicating the WFA does not impair the clearance 
of autophagosomes.
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Figure 1. WFA induces autophagosome accumulation, LC3B conversion and other autophagy related proteins. (A) MCF7 and MDA-MB-231 cells were treated with 5 µM WFA 
for 3 and 6 h as indicated and visualized under an electron microscope. Scale bars: 2 µm. Pictures are shown with ~×7400 magnifications. Double-membrane autophagosomes 
were counted in randomly selected ~100 cells. The number of autophagosomes was counted from randomly selected fields (shown in bar graphs). *P < 0.005, compared 
with vehicle-treated controls (C). (B) Breast cancer cells were treated with 5 µM WFA and subjected to immunocytochemistry using an LC3B antibody. Scale bars: 20 µm. 
Representative immunofluorescence images are shown. Bar diagram shows number of LC3B puncta per cell. *P < 0.001, compared with vehicle-treated controls (C). (C) Breast 
cancer cells were treated with 5 µM WFA, and total cell lysates were immunoblotted for LC3B (14, 16 kDa) expression. ACTB (45 kDa) was used as a loading control. (D) Total 
protein lysates from MDA-MB-231-derived tumors from vehicle-treated and WFA-treated mice were examined for the expression of LC3B (14, 16 kDa). ACTB (45 kDa) was 
used as a loading control. (E) Immunoblot analysis of ATG5 (55 kDa), ATG7 (78 kDa), and BECN1 (60 kDa) in breast cancer cells treated with 5 µM WFA as indicated. ACTB 
(45 kDa) was used as a loading control. (F) Tumors from vehicle and WFA-treated mice were subjected to immunohistochemical (IHC) analysis using LC3B antibodies. Scale 
bars: 100 µm. Bar diagrams show quantification of IHC analysis. *P< 0.01, compared with control. (G) Breast cancer cells were treated with 5 µM WFA, and total RNA were 
examined for the expression of ATG5, ATG7 and BECN1. ACTB was used as a loading control. (H) Schematic diagram of the tfLC3 plasmid (upper panel). MDA-MB-231 and 
MCF7 cells were transfected with tfLC3 followed by treatment with 5 µM WFA or 200 nM rapamycin or Earle’s balanced salt solution. Earle’s balanced salt solution and 
rapamycin were used as positive controls for autophagic induction. Representative fluorescent images are shown. Scale bar: 20 μm.
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WFA augments the fusion of autophagosomes and 
lysosomes
Late stage of autophagy, the fusion of autophagosomes with 
lysosomes, can be investigated by staining for GFP-LC3B 
(decorating autophagosomes) along with LysoTracker Red 
(an acidic pH marker for lysosomes). Confocal microscopy 
of WFA-treated cells showed increased overlap of GFP-LC3B 
and LysoTracker Red signals (increased yellow puncta) in 
comparison to control cells indicating an increased fusion of 
autophagosomes and lysosomes (Figure 2A). RAB7, a member 
of small GTPases, is one of the important molecules involved 
in the maturation of autolysosomes in both the endolysosomal 
and autophagic pathways (29,30). MCF7 and MDA-MB-231 cells 
were cotransfected with GFP-LC3B and RFP-Rab7 plasmids and 
autophagosomes (GFP positive/RFP negative; green puncta), 
autolysosomes (RFP positive/GFP negative; red puncta) and 
autolysosomes fusion (GFP positive/RFP positive; yellow puncta) 
were examined. Confocal analyses showed that withaferin 
treatment resulted in a significant overlap of LC3B and Rab7 
signals compared with control cells indicating that WFA 
treatment led to fusion of autophagosomes and lysosomes 
(Figure 2B). Next, we evaluated autolysosomal pH using acridine 
orange (AO) staining as autolysosomes are characterized by 
acidic pH. Upon WFA treatment, nucleus and cytoplasm exhibited 
green fluorescence whereas the acidic compartments showed 
orange and red fluorescence. We observed that autolysosomes 
have the characteristics of acidic compartments in WFA-treated 
cells (Figure 2C and D). Together, WFA increases the fusion of 
autophagosomes and lysosomes to form autolysosomes.
Impairment of autophagic process fails to protect 
cells against WFA induced growth inhibition and 
apoptosis induction
Having observed WFA-mediated increased autophagosome 
turnover and autolysosome formation, we evaluated the 
role of autophagy in WFA-induced apoptotic induction and 
Figure 2. WFA induces the fusion of autophagosomes and lysosomes. (A) MCF7 and MDA-MB-231 cells were transfected with GFP-LC3B followed by treatment with 
5 µM WFA or Earle’s balanced salt solution (2 h) and staining with LysoTracker Red. Cells were fixed and subjected to confocal microscopy. Representative fluorescent 
images are shown. Scale bar: 10 μm. Earle’s balanced salt solution was used as positive control for autophagic induction. (B) MCF7 and MDA-MB-231 cells were 
cotransfected with GFP-LC3B and RFP-RAB7 followed by treatment with 5 µM WFA or Earle’s balanced salt solution (2  h). Fixed cells were subjected to confocal 
microscopy. Representative fluorescent images are shown. Scale bars: 10 μM. (C) MCF7 and MDA-MB-231 cells were treated with 2.5 and 5 µM WFA followed by acridine 
orange staining. Representative images of MCF7 cells are shown. Scale bar: 10 μm. (D) Bar graph shows acridine orange punta per cell in MCF7 and MDA-MB-231 cells. 
*P< 0.01, compared with control.
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growth inhibition. We blocked autophagy in WFA-treated 
cells using 3-MA, a phosphatidylinositol 3-kinase (PtdIns3K/
Vps34) inhibitor that impedes autophagosome formation 
(31) or Baf, a specific vacuolar type H+-ATPase inhibitor that 
prevents autophagosome–lysosome fusion (32) or CQ, a weak 
base that elevates lysosomal pH. Interestingly, WFA-mediated 
inhibition of growth of breast cancer cells remained unaltered 
upon combined treatment with 3-MA, CQ or Baf (Figure 3A, 
Supplementary Figure S6, available at Carcinogenesis Online). 
Also, the magnitude of apoptotic cell death observed upon 
WFA treatment was unaffected when breast cancer cells were 
co-treated with autophagy inhibitors 3-MA, CQ or Baf (Figure 3B). 
Immunoblot analysis of MCF7 and MDA-MB-231 cells treated 
with combination of WFA and 3-MA showed equivalent levels of 
cleavage of PARP1 in comparison to WFA treatment alone (Figure 
3C). Concomitant actions of many ATG proteins are required in 
autophagy (18). As a genetic intervention, we knocked out (KO) 
BECN1 and ATG7 in MCF7 cells using CRISPR/Cas9 technology 
(Figure 3D). Treatment with WFA-induced PARP1 cleavage in 
vector control cells as well as in BECN1-KO and ATG7-KO cells 
(Figure 3E). Moreover, WFA-mediated inhibition of clonogenic 
growth of breast cancer cells was not impacted upon BECN1 and 
ATG7 knockout as BECN1-KO and ATG7-KO MCF7 cells showed 
similar growth inhibition upon WFA treatment as vector-control 
MCF7 cells (Figure 3F). BECN1-KO and ATG7-KO MCF7 cells also 
showed significant decrease in cell viability upon WFA treatment 
analogous to vector control MCF7 cells (Figure 3G). Collectively, 
these data provide evidence that WFA induced cell death is not 
an ‘autophagic cell death’.
WFA treatment inhibits lysosomal activity
A key step in autophagic process is the degradation of cargo 
in the autolysosomes. We questioned whether WFA treatment 
affected lysosomal activity in breast cancer cells, therefore, 
lysosomal proteolytic activity was assayed using DQ-BSA (a 
derivative of BSA whose green fluorescence is quenched except 
when it is cleaved by proteolytic enzymes) assay. Earle’s balanced 
salt solution starvation and rapamycin treatment exhibited 
stimulated lysosomal activity as evident by dequenching of 
DQ-BSA in lysosomes. WFA treated cells showed decreased 
DQ-BSA emission (green puncta) in lysosomes (red puncta) 
as indicated by colocalization with LysoTracker Red (merge 
Figure 3. Inhibition of autophagy does not impact WFA-mediated inhibition of cell survival and apoptosis induction in breast cancer cells. (A) MCF7 and MDA-MB-231 
cells were treated with 5 µM WFA alone or in combination with 200 nM Baf, 25 μM CQ and 4 mM 3-MA as indicated and subjected to MTT assay. *P< 0.001, compared with 
control. (B) Breast cancer cells were treated with 5 µM WFA alone or in combination with 25 μM CQ and 4 mM 3-MA as indicated and subjected to DNA fragmentation 
assay. *P< 0.01, compared with control. (C) MCF7 and MDA-MB-231 cells were treated with 5 µM WFA and 4 mM 3-MA and total cell lysates were immunoblotted for 
cleaved PARP1 (cPARP1, 89 kDa), PARP1 (116 kDa) and ACTB (45 kDa) as indicated. (D) CRISPR/Cas9 was used to knockout BECN1 and ATG7 in MCF7 cells and total cell 
lysates were immunoblotted for BECN1 (60 kDa) and ATG7 (78 kDa). ACTB (45 kDa) was used as loading control. (E) Vector-control, BECN1-KO and ATG7-KO MCF7 cells 
were treated with 5 µM WFA for indicated time intervals and total cell lysates were immunoblotted for cleaved-PARP1 (89 kDa) and total-PARP1 (116 kDa) expression 
levels. ACTB (45 kDa) was used as loading control. (F) Clonogenicity of control, BECN1-KO and ATG7-KO MCF7 cells treated with 5 µM WFA as indicated. (G) Cell viability 
of control, BECN1-KO and ATG7-KO MCF7 cells treated with 5 µM WFA was examined using MTT assay. Representative pictures of cells are shown.
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showing increased red puncta) (Figure 4A and B). Reduction in 
SQSTM1/p62 level is linked with increased autophagic activity 
as SQSTM1/p62 interacts with ubiquitin protein and LC3B-II and 
gets degraded in the autolysosomes, therefore, we investigated 
the levels of SQSTM1/p62 in breast cancer cells treated with 
WFA. WFA-treated breast cancer cells and MDA-MB-231 
xenografts showed increased SQSTM1/p62 levels (Figure 4C and 
D). Immunohistochemical analysis of MDA-MB-231 xenograft 
tumors from WFA-treated mice showed increased expression 
of SQSTM1/p62 in comparison to tumors from vehicle-treated 
mice (Figure 4E). Cathepsin (CTS) proteases are implicated as 
important lysosomal hydrolases that degrade the sequestered 
components. Using lysosomes isolated from WFA-treated cells, 
we found that WFA impaired the maturation of Cathepsin D 
(CTSD) (Figure 4F). Inhibition of CTSD maturation also indicated 
reduced CTSB and CTSL activity as they are essential for the 
cleavage of CTSD. WFA treated cells show reduced levels of 
CTSD (Figure 4G). Together, these results present that while WFA 
does not inhibit the fusion of autophagosomes and lysosomes, 
it impairs autophagic flux by inhibiting lysosomal activity in 
breast cancer cells.
WFA induces growth inhibition and apoptotic 
induction by energy depletion in breast cancer cells
It is important to note that blockade in lysosomal proteolytic 
activity reduces the recycling of cellular fuels, that can result in 
insufficient energy leading to growth inhibition and cell death 
(33). To examine whether WFA affects cellular energy levels in 
breast cancer cells, we measured the intracellular production of 
ATP levels in breast cancer cells treated with WFA and found 
that ATP levels were 70–80% reduced within 24 h post-treatment 
(Figure 5A, Supplementary Figure S3E, available at Carcinogenesis 
Online). AMPK, sensor of cellular energy status, gets activated 
in response to the modulation of AMP/ATP ratio to maintain 
cellular energy homeostasis. Indeed, Thr172 phosphorylation 
of the PRKAA1, catalytic subunit of AMPK, was increased in 
WFA-treated MCF7 and MDA-MB-231 breast cancer cells (Figure 
5B) and MDA-MB-231 xenograft tumors from WFA-treated 
Figure 4. WFA inhibits protein degradation in lysosomes. (A, B) MCF7 and MDA-MB-231 cells were incubated with 10 μg/ml DQ-BSA for 2 h followed by washing with 
medium and treatment with 5 µM WFA or 200 nM rapamycin or starving in Earle’s balanced salt solution. The cells were fixed and stained with LysoTracker Red 
followed by confocal microscopy. Earle’s balanced salt solution and rapamycin were used as positive controls for autophagic induction. Representative fluorescent 
images are shown. Scale bars: 10 μM. (C) Breast cancer cells were treated with 5 µM WFA for indicated time intervals and total lysates were immunoblotted for SQSTM1 
(62 kDa) expression levels. ACTB (45 kDa) was used as loading control. (D) Total protein lysates from MDA-MB-231-derived xenograft tumors from vehicle-treated and 
WFA-treated mice were examined for the expression of SQSTM1 (62 kDa). ACTB (45 kDa) was used as a loading control. (E) Tumors from vehicle and WFA-treated mice 
were subjected to immunohistochemical (IHC) analysis using SQSTM1 antibodies. Scale bars: 100 µm. Bar diagrams show quantification of IHC analysis. *P < 0.01, 
compared with control. (F) MDA-MB-231 and SUM159 breast cancer cells were treated with 5 µM WFA followed by lysosome extraction. Total lysates and lysosomes were 
immunoblotted for cathepsin D (CTSD). LAMP2 (130 kDa) was used as control. (G) Immunocytochemical analysis of cathepsin D in breast cancer cells treated with WFA.
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mice (Supplementary Figure S7A, available at Carcinogenesis 
Online). Inhibition of AMPK activation with compound C 
reduced anti-cancer efficacy of WFA whereas AMPK activator 
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) 
ameliorated the effects of WFA (Supplementary Figure S7B–E, 
available at Carcinogenesis Online). 2-DG is a glucose analog that 
decreases cellular ATP production resulting in AMPK activation 
leading to inhibition of cancer cell growth (29). Indeed, combined 
treatment of WFA and 2-DG resulted in a significant decrease in 
cellular ATP levels (Figure 5C) and increased apoptosis induction 
and growth inhibition of breast cancer cells in comparison 
to either treatment alone (Figure 5D, F and G). WFA and 2-DG 
treatment also showed higher cleavage of PARP1 in breast 
cancer cells (Figure 5E). Importantly, WFA and 2-DG induced 
synergistic cytotoxic effect in HCC1569, HCC1806, Hs578t, MCF7, 
MDA-MB-231 and MDA-MB-468 cells. Combination index (CI) 
analyses was performed using CompuSyn software to analyze 
the combined effect of WFA and 2-DG in breast cancer cells. CI 
< 1 shows synergism, CI = 1 shows additivity and CI > 1 shows 
antagonism and notably, in multiple combinations of WFA and 
2-DG, CI values were less than 1 (Figure 6A and B).
Decrease in cellular ATP levels might reflect an insufficiency 
of TCA carbon substrates; therefore, we incubated breast cancer 
cells with methyl pyruvate (MP) as a source of substrate for 
the TCA cycle. Excess MP not only restored ATP levels in WFA-
treated cells (Figure 6C) but also protected breast cancer cells 
against WFA-induced growth inhibition and apoptotic induction 
(Figure 6D, E). As expected, MP inhibited WFA-induced cleavage 
of PARP1 in breast cancer cells (Figure 6F). Normal proliferating 
cells produce ATP through oxidative phosphorylation in the 
mitochondria while proliferating cancer cells largely depend 
on aerobic glycolysis to meet their high energy requirements 
in the presence of adequate oxygen. Glucose gets converted 
to pyruvate during glycolysis and cancer cells preferentially 
transform pyruvate to lactate in the cell cytoplasm instead 
of utilizing TCA cycle in mitochondria (Figure 6G). LDHA is an 
important enzyme that drives the increased flow of metabolites 
through this aberrant metabolic pathway by catalyzing the 
conversion of pyruvate to lactate (30). LDHA is considered an 
ideal target to mitigate the cellular energy supply in cancer 
cells (34). We found that WFA treatment effectively reduces 
the expression of LDHA in breast cancer cells (Figure 6H 
and I). Tyrosine phosphorylation of LDHA promotes cellular 
metabolism and plays an important role in tumor growth 
promotion (35), therefore, we investigated the impact of WFA 
treatment on LDHA phosphorylation levels. Interestingly, WFA 
treatment effectively reduced Y10 phosphorylation of LDHA 
in MDA-MB-231 and MCF7 breast cancer cells (Figure 6I). We 
Figure 5. WFA induces energy impairment with AMPK activation. (A) Breast cancer cells were treated with 5 µM WFA for the indicated time intervals and intracellular 
ATP production was measured. Relative ATP levels are expressed with respect to the control. *P< 0.005, compared with control. (B) Breast cancer cells were treated 
with 5 µM WFA for indicated time intervals and total lysates were immunoblotted for phospho-PRKAA1 (p-PRKAA1) and total PRKAA1 (62 kDa) expression levels. ACTB 
(45 kDa) was used as loading control. (C) SUM149 and SUM159 cells were treated with 5 µM WFA alone or in combination with 2-DG as indicated. Intracellular ATP 
production was measured. Relative ATP levels are expressed with respect to the control. *P< 0.005, compared with control; **P< 0.01, compared with WFA alone. (D) 
SUM149 and SUM159 cells were treated with 5 µM WFA alone or in combination with 2-DG as indicated followed by Hoechst 33342 staining apoptosis detection. Mean 
number of apoptotic cells are presented in bar graphs. *P< 0.01, compared with control; **P< 0.01, compared with WFA alone. (E) Breast cancer cells were treated with 
5 µM WFA alone or in combination with 2-DG as indicated. Total lysates were immunoblotted for the expression of cPARP1 (89 kDa) and PARP1 (116 kDa). ACTB (45 kDa) 
was used as loading control. (F, G) SUM149 and SUM159 cells were treated with 5 µM WFA alone or in combination with 2-DG as indicated and subjected to Trypan Blue 
exclusion assay. Bar graph shows percentage of alive cells. *P< 0.01, compared with control; **P< 0.005, compared with WFA alone.
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found that WFA treatment increases AMPK and decreases LDHA 
in breast cancer cells and intriguingly, high-AMPK and low-
LDHA expression associate with better relapse-free survival in 
breast cancer patients (Figure 6J). The entire combined dataset 
contained 4374 patients, of which 696 were estrogen receptor 
(ER) negative and HER2 negative (hence on termed as TNBC 
cohort). The mean follow-up of all patients was 71.5  months. 
In all patients, higher expression of AMPK correlated to better 
survival (n = 4374, P = 1.3e-05, HR = 0.75) and when restricted 
to TNBC patients, the correlation trend remained (n  =  696, 
P  =  0.1, HR  =  0.81). At the same time, an opposite association 
was observed for LDHA as higher expression resulted in worse 
survival outcomes (in all patients P  =  1.6e-16, HR  =  1.59). The 
effect of LDHA was more pronounced in TNBC patients (P = 4.9e-
05, HR = 1.64) (Figure 6J).
Collectively, our data uncovers a sequence of events where 
WFA blocks autophagic flux by inhibiting proteolytic lysosomal 
activity and leads to insufficient substrates for TCA cycle, 
inhibits LDHA, leading to energy insufficiency and consequently 
to growth inhibition and apoptotic induction.
Discussion
Finding new therapeutic strategies that can inhibit carcinogen-
esis in an effective, non-toxic and non-endocrine manner is a 
major goal of breast cancer research. Autophagy is important for 
the survival of cancer cells as it helps maintain the cellular energy 
supply and homeostasis in rapidly proliferating cancer cells and 
helps evade various environmental and cellular stresses (36). In 
this study, we show that WFA is a potent inhibitor of lysosomal 
proteolytic activity, blocks autophagic flux and exerts antitumor 
activity in multiple subtypes of breast cancer including luminal 
A, luminal B, basal, claudin-low, and HER2 subtypes. We 
established a connection between autophagy inhibition, energy 
depletion and cell death in WFA-treated breast cancer cells. 
Upon observing increased autophagosome formation, LC3B con-
version and LC3B puncta in WFA-treated breast cancer cells, we 
further investigated the effects of WFA on autophagic flux using 
several different approaches as limiting the assessment to the 
number of autophagosomes and LC3B levels is insufficient to 
gauge the entire autophagic process and its biological impact. 
Autophagy can be limited due to the delayed trafficking of 
autophagosomes to lysosomes, the fusion of autophagosomes 
and lysosomes, or defects in lysosomal proteolytic activity (27). 
Confocal analyses of tandem GFP-RFP-tagged LC3B fluorescence, 
LysoTracker Red assay and the colocalization of GFP-LC3B 
and RFP-RAB7 showed that WFA increases the fusion of 
autophagosomes and lysosomes. Autophagosome and lysosome 
fusion is regulated by the internal pH in acidic organelles (37) 
and indeed, AO staining shows that lysosomes display the 
characteristics of acidic compartments in WFA-treated cells. 
By definition, autophagy is self-eating process that recycles 
damaged cellular organelles, long-lived cytoplasmic protein and 
glycogen in a lysosome-dependent process (17,18). These cellu-
lar components are delivered to the autolysosome followed by 
their breakdown by lysosomal hydrolases—cathepsin proteases. 
Our data from DQ Green BSA assay showed that WFA abrogates 
lysosomal function and inhibits the maturation of cathepsins. 
With careful analyses of multiple steps of autophagic process, 
we uncovered that although WFA-treated breast cancer cells 
show the upregulation of initial steps of autophagy, WFA blocks 
autophagic flux by inhibiting lysosomal proteolytic activity.
Interestingly, our data excludes an ‘autophagic cell death’ in 
WFA-treated cells as inhibiting autophagy with 3-MA, CQ, Baf or 
ATG7 and BECN1 knockdown fails to rescue WFA-treated cells, and 
instead shows the involvement of energetic impairment in WFA-
mediated growth inhibition and apoptosis induction. Indeed, MP 
treatment could protect WFA-treated breast cancer cells. Going in 
line with the notion that blocking autophagic flux would impact 
the availability of substrates for both biosynthesis and energy 
generation (36), our results demonstrate that WFA reduces cellular 
ATP production altering the AMP:ATP ratio leading to a significant 
increase in PRKAA1 phosphorylation in breast cancer cells. 
Inhibition of PRKAA1 with compound C reduces WFA-mediated 
growth inhibition and apoptotic induction while PRKAA1 activator 
AICAR potentiates WFA’s effect in breast cancer cells indicating 
the functional importance of PRKAA1 in WFA action. 2-DG, an 
analog of glucose that is effectively taken up by cells but inhibits 
hexokinase, leads to inhibition of glycolysis and intracellular 
ATP depletion (38). Targeting tumor energy pathways with 2-DG 
treatment has been shown to induce PRKAA1 activation leading 
to growth inhibition in multiple preclinical models (39,40). Our 
data show that combined treatment with 2-DG and WFA further 
reduces ATP levels and exhibits more effective reduction of cell 
growth and induction of apoptotic cells. Clinical studies utilizing 
2-DG to target tumor metabolism have shown safety and efficacy 
of 2-DG in prostate cancer (41), advanced solid tumors (42) and 
cerebral gliomas (43). In light of our observations, combination of 
2-DG and WFA might be useful in targeting metabolic fragility of 
breast cancer cells.
Cancer cells preferentially utilize aerobic glycolysis to 
metabolize glucose in contrast to normal proliferating cells that 
produce ATP via oxidative phosphorylation in the mitochondria 
(30). Conversion of pyruvate and NADH to lactate and NAD+ during 
glycolysis is catalyzed by LDHA, a key enzyme that promotes the 
metabolic switch to aerobic glycolysis (44). Cancer cells exhibit 
higher expression levels of LDHA along with elevated tyrosine 
phosphorylation of LDHA (45,46). Phosphorylation of LDHA 
is more abundant in breast tumors in comparison to normal 
adjacent tissues and correlates with increased invasive and 
metastatic potential. Intriguingly, we found that WFA inhibits 
LDHA expression as well as phosphorylation at Y10 in breast 
cancer cells (47). These findings have important implications as 
LDHA is fast emerging as an anti-cancer target bridging the gap 
between metabolic perturbations and metastatic progression of 
cancer cells. Recognition of LDHA as an anticancer target has 
fueled the interest in developing LDHA inhibitors but very few 
LDHA inhibitors with in vivo efficacy have been reported so far. 
Earliest reported LDH inhibitor is oxamate that inhibits LDH 
activity by blocking the pyruvate binding site but it is a weak 
inhibitor. Diallyl trisulfide (DATS), an organo-sulfur compound 
from garlic, was reported to decrease LDHA in triple negative 
breast cancer cells. A small molecule inhibitor of LDHA, GNE-140, 
has shown effective inhibition of LDHA in pancreatic tumor cells. 
Some new inhibitors have also been developed but only few have 
shown in vivo efficacy (47). In this regard, recognition of WFA as 
an LDHA inhibitor in breast cancer cells is important as WFA has 
shown in vivo efficacy in multiple breast cancer models (12).
Conclusions
In conclusion, our study presents that WFA impairs proteolytic 
lysosomal activity causing blockade of autophagic flux resulting 
in energy depletion leading to growth inhibition and apoptotic 
induction. Our results also show that WFA is an AMPK activator 
that works synergistically with 2-DG to inhibit breast cancer 
growth and is also an inhibitor of LDHA. These attributes of WFA 
support its development as a potential cancer chemopreventive 
and chemotherapeutic agent for breast cancer.
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Figure 6. Combined treatment with WFA and 2-DG synergistically inhibits breast cancer cells. WFA induces energy impairment with reducing LDHA and higher expression 
of AMPK and low expression of LDHA correlates with increased overall survival. (A, B) HCC1569, HCC1806, HS578t, MDA-MB-231 and MDA-MB-468 breast cancer cells were 
treated with various concentrations of WFA (1.0, 2.5, 5.0. 7.5, 10.0 µM) in combination with 4.0 mM of 2-DG. MCF7 cells were treated with various concentrations of WFA in 
combination with 2.0 mM 2-DG. Cells were subjected to XTT assay and combination index values were calculated using CompuSyn software. CI < 1 represents synergism. 
Table shows combination index of different concentrations of WFA and 2-DG. (C) MCF7 cells were treated with 5 µM WFA or 10 mM MP as indicated and intracellular ATP 
production was measured. Relative ATP levels are expressed with respect to the control. *P< 0.01, compared with control; **P< 0.005, compared with WFA alone. (D) MCF7 
cells were treated with 5 µM WFA or 10 mM MP as indicated and subjected to Trypan Blue exclusion assay. Bar graph shows fold change of alive cells. *P< 0.01, compared 
with control; **P< 0.001, compared with WFA alone. (E) MCF7 cells were treated with 5 µM WFA or 10 mM MP as indicated followed by Hoechst 33342 staining apoptosis 
detection. Mean number of apoptotic cells are presented as fold change in bar graphs. *P < 0.01, compared with control; **P< 0.01, compared with WFA alone. (F) Total 
lysates were immunoblotted for the expression of cPARP1 (89 kDa) and PARP1 (116 kDa). ACTB (45 kDa) was used as loading control. (G) Schematic representation of TCA 
cycle and aerobic glycolysis in proliferating cancer cells. Role of LDHA is noted. (H) Breast cancer cells were treated with 5 µM WFA for various time intervals as indicated. 
Total RNA was examined for the expression of LDHA using RT-PCR. ACTB was used as loading control. (I) Breast cancer cells were treated with 5 µM WFA for various time 
intervals as indicated. Total lysates were immunoblotted for the expression of LDHA (37 kDa) and phospho-LDHA (p-LDHA). ACTB (45 kDa) was used as loading control. (J) 
In breast cancer patients, higher expression of AMPK and lower expression of LDHA correlate to better prognosis (n = 4,374, HR = 0.75, P = 1.3e-05 and HR = 1.59, P = 1.6e-
16, respectively). When investigating ER negative HER2 negative patients, the correlation to better survival was more prominent in LDHA (HR = 1.64, P = 4.7e-05) but was 
smaller for AMPK (HR = 0.81, P = 0.1). The plots display relapse free-survival, ER and HER2 status were determined using gene expression.
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